Subcutaneous Amivantamab and Administration Considerations

The FDA approval of subcutaneous amivantamab with monthly dosing represents a significant advancement in treatment convenience. Dr. Devarakonda emphasizes that while toxicity concerns shouldn't discourage effective regimen use, practical barriers including time and supportive care requirements make subcutaneous administration valuable.

The subcutaneous formulation reduces infusion-related reactions from 60% to 20%, though Dr. Camidge notes that 20% still represents an unacceptably high rate for a new regimen. The 10-minute administration versus hours-long IV infusions provides substantial convenience for patients managing work and family responsibilities.

Critical patient support system modifications are necessary for successful amivantamab use, particularly for non-English speaking populations. Dr. Devarakonda describes implementing 24/7 interpreter services and multilingual medication labeling, as patients receiving 14 pill bottles with English-only labels cannot manage complex prophylaxis regimens effectively.

Scalp toxicity management requires specific interventions since patients cannot examine their own scalps and may hide symptoms due to perceived hygiene concerns. Caregiver education about scalp examination and early reporting proves essential for toxicity prevention.

Dr. Lopes notes that subcutaneous formulation doesn't eliminate cutaneous toxicities, infusion reactions (though reduced), or DVT risk requiring continued prophylaxis. Some patients experience headaches during induction phases, mimicking CNS progression and leading to unnecessary imaging in EGFR-mutant populations already at high CNS risk.

The panel emphasizes that while subcutaneous administration improves convenience and reduces some toxicities, comprehensive supportive care regimens including skin prophylaxis and careful monitoring remain essential for safe amivantamab administration.